Search results for " PSORIASIS"

showing 10 items of 32 documents

Latent tubercolosis infection in patients with cronic plaque psoriasis: evidence from the Italian Psocare Registry

2015

SummaryBackground The nationwide prevalence of latent tuberculosis infection (LTBI) in Italian patients with psoriasis has never been investigated. Objectives To estimate the nationwide prevalence of LTBI in Italian patients with psoriasis who are candidates for systemic treatment. Methods Data were obtained from the Psocare Registry on those patients (n = 4946) with age > 18 years, systemic treatment at entry specified and tuberculin skin test (TST) performed according to the Mantoux method. LTBI diagnosis was based on a positive TST result in the absence of any clinical, radiological or microbiological evidence of active tuberculosis. Results Latent tuberculosis infection was diagnosed in…

RegistrieMaletaiwanAntitubercular AgentsBiological Factorquantiferon-tb-goldAntitubercular AgentBiological FactorsexperienceResidence Characteristics80 and overPrevalenceRegistriesYoung adultriskAged 80 and overLatent TuberculosiLatent tuberculosispsoriasisMiddle AgedItalyFemaletubercolosistubercolosiAdolescent; Adult; Age Distribution; Aged; Aged 80 and over; Antitubercular Agents; Biological Factors; Chronic Disease; Female; Humans; Italy; Latent Tuberculosis; Male; Middle Aged; PUVA Therapy; Prevalence; Psoriasis; Registries; Residence Characteristics; Sex Distribution; Tuberculin Test; Young Adult; 2708Humanmedicine.drugAdultmedicine.medical_specialtyAdolescentchronic plaque psoriasisTuberculinconsensus statementtubercolosis; psoriasisDermatology.Young Adulttuberculosis infectionSettore MED/35Age DistributionLatent TuberculosisInternal medicinePsoriasismedicineAdalimumabfactor antagonistsHumansPsoriasisnecrosis-factor blockers; quantiferon-tb-gold; consensus statement; factor antagonists; systemic treatment; therapy; experience;taiwan; assay; risknecrosis-factor blockersSex DistributionAdolescent; Adult; Age Distribution; Aged; Aged 80 and over; Antitubercular Agents; Biological Factors; Chronic Disease; Female; Humans; Italy; Latent Tuberculosis; Male; Middle Aged; PUVA Therapy; Prevalence; Psoriasis; Registries; Residence Characteristics; Sex Distribution; Tuberculin Test; Young AdultPUVA TherapyAgedPsoriasiHistory of tuberculosistherapytuberculosis infection chronic plaque psoriasisItalian Psocare Registrybusiness.industryTuberculin TestOdds ratiosystemic treatmentassaymedicine.diseasebacterial infections and mycosesConfidence intervalSurgeryResidence CharacteristicChronic DiseaseItalian Psocare Registrybusiness2708
researchProduct

Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry

2014

Background: Some studies have shown that switching patients from one tumor necrosis factor (TNF)-alfa inhibitor to another may be beneficial when they have an inadequate response or an adverse event. Objective: We sought to assess the variables predicting the efficacy of the second TNF-alfa inhibitor in patients discontinuing the first TNF-alfa inhibitor. Methods: Data from all 5423 consecutive patients starting TNF-alfa inhibitor therapy for psoriasis between September 2005 and September 2010 who were included in the Italian Psocare registry were analyzed. Results: In 105 patients who switched to a second TNF-alfa inhibitor who had complete follow-up data, 75% improvement in the Psoriasis …

Maleprimary inefficacy75% improvement in the Psoriasis Area Severity Index score; PASI; PASI 75; Psoriasis Area Severity Index; TNF; biologics; efficacy; primary inefficacy; psoriasis; secondary loss of efficacy; switching; tumor necrosis factor; tumor necrosis factor-alfa inhibitors; Adult; Analysis of Variance; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Cohort Studies; Confidence Intervals; Dose-Response Relationship Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunoglobulin G; Italy; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Proportional Hazards Models; Psoriasis; Receptors Tumor Necrosis Factor; Registries; Retrospective Studies; Risk Assessment; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha; Young AdultSWITHCESefficacyTNFpsoriasis; psoriasis arthritis; pharmachological treatmentPASI 75Severity of Illness IndexReceptors Tumor Necrosis FactorEtanerceptCohort StudiesMonoclonalReceptorsSettore MED/35 - Malattie Cutanee E VenereeRegistriesHumanizedtumor necrosis factor-alfa inhibitors.switchingHazard ratioAntibodies MonoclonalMiddle AgedTreatment OutcomeItalyPredictive value of tests75% improvement in the Psoriasis Area Severity Index scoreFemaleDrugPsoriasis Area Severity IndexbiologicTNF-alphaAdultmedicine.medical_specialtytumor necrosis factorDermatology75% improvement in the Psoriasis Area Severity Index score; PASI; PASI 75; Psoriasis Area Severity Index; TNF; biologics; efficacy; primary inefficacy; psoriasis; secondary loss of efficacy; switching; tumor necrosis factor; tumor necrosis factor-alfa inhibitorsAntibodies Monoclonal Humanizedsecondary loss of efficacyRisk AssessmentAntibodiestumor necrosis factor-alfa inhibitorsDrug Administration ScheduleDose-Response RelationshipYoung AdultSettore MED/35Predictive Value of TestsInternal medicinePsoriasisSeverity of illnessmedicineConfidence IntervalsHumansPsoriasisbiologicsAdverse effectPsoriasis; TNF-alphaProportional Hazards ModelsRetrospective Studiespsoriasibiologics; efficacy; primary inefficacy; psoriasis; secondary loss of efficacy; switching; tumor necrosis factor-alfa inhibitors; Adalimumab; Adult; Analysis of Variance; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Cohort Studies; Confidence Intervals; Dose-Response Relationship Drug; Drug Administration Schedule; Etanercept; Female; Follow-Up Studies; Humans; Immunoglobulin G; Infliximab; Italy; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Proportional Hazards Models; Psoriasis; Receptors Tumor Necrosis Factor; Registries; Retrospective Studies; Risk Assessment; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult; 2708Analysis of Variancepharmachological treatmentDose-Response Relationship DrugProportional hazards modelbusiness.industrytumor necrosis factor-alfa inhibitorTumor Necrosis Factor-alphaPASIAdalimumabRetrospective cohort studypsoriasis arthritismedicine.diseaseConfidence intervalInfliximabSurgeryImmunoglobulin GMultivariate AnalysisANTI-TNFAbusiness2708Follow-Up Studies
researchProduct

Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic. risk analysis from the PSO-BIO-COVI…

2021

Background The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and …

0301 basic medicineMaleClinical BiochemistryDiseaseCohort Studies0302 clinical medicineDrug DiscoveryReceptors80 and overMedicineAged 80 and overeducation.field_of_studyIncidence (epidemiology)IncidenceInterleukin-17psoriasisMiddle Ageddermatologysars-CoV-2Italybiological therapy030220 oncology & carcinogenesisCohortBiological ProductCOVID-19; biological therapy; dermatology; psoriasis; sars-CoV-2FemaleSettore MED/35 - MALATTIE CUTANEE E VENEREEbiological therapy; COVID-19; dermatology; psoriasis; sars-CoV-2; Adult; Aged; Aged 80 and over; Biological Products; Biological Therapy; COVID-19; Chronic Disease; Cohort Studies; Female; Humans; Incidence; Interleukin-17; Italy; Male; Middle Aged; Pandemics; Psoriasis; Receptors Interleukin; Risk Assessment; Tumor Necrosis Factor-alpha; Young AdultCohort studyHumanAdultmedicine.medical_specialtyPopulationRisk AssessmentCOVID-19; psoriasis; biological therapy; dermatology; sars-CoV-203 medical and health sciencesYoung AdultSettore MED/35Internal medicinePsoriasisPsoriasis.HumanseducationPandemicsAgedPharmacologyPsoriasiBiological ProductsPandemicbiological therapy; COVID-19; dermatology; psoriasis; sars-CoV-2business.industryTumor Necrosis Factor-alphaCOVID-19Receptors InterleukinBiological productInterleukinmedicine.diseaseClinical trial030104 developmental biologyChronic DiseaseCOVID-19; SARS-CoV-2; biological therapy; dermatology; psoriasisCohort Studiebusiness
researchProduct

Managing the Systemic Impact of Periodontitis

2022

Periodontitis is a microbially driven host-mediated disease that leads to loss of periodontal attachment and bone. It is associated with elevation of systemic inflammatory markers and with the presence of systemic co-morbidities. Furthermore, periodontal treatment leads to a 24–48 h-long acute local and systemic inflammatory response. This systemic response might increase the burden of patients with compromised medical history and/or uncontrolled systemic diseases. The correlation between periodontitis and systemic diseases, the impact of periodontitis on the quality of life and public health, the effects of periodontal treatment on systemic health and disease, and the available methods to …

Quality of lifeInflammationPublic healthGeneral MedicineMetabolic syndromePregnancy outcomebiomarkers cardiovascular diseases diabetes mellitus inflammation metabolic syndrome periodontitis pregnancy outcome psoriasis public health quality of lifeCardiovascular diseasesDiabetes mellitusQuality of LifePsoriasisHumansPeriodontitisBiomarkers
researchProduct

Improved effectiveness from individualized dosing of self-administered biologics for the treatment of moderate-to-severe psoriasis: a 5-year retrospe…

2019

Background: Biologics for moderate-to-severe psoriasis are expensive and treatment substitutions may vastly increase cost. Moreover, administration regimens in routine practice may differ from recommended guidelines. Objectives: To evaluate long-term effectiveness, regimen, drug-survival, and efficiency of self-administered biologics in clinical practice. Methods: We performed a 5-year retrospective study in 72 patients (44 ± 14 years old) with moderate-to-severe psoriasis at the University Hospital La Plana (Vila-real, Spain), treated with subcutaneous biologics. We determined the effectiveness (PASI 75 or PASI < 5), and drug-survival using Kaplan-Meier estimates, and analyzed reasons for …

AdultMalemedicine.medical_specialtyIndividualized dosingCost effectivenessefficacySelf AdministrationKaplan-Meier EstimateDermatologyRoutine practiceDrug CostsustekinumabEtanercept030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineChart reviewPsoriasisUstekinumabmedicineHumansPsoriasisbiologicsIntensive care medicinecost-effectivenessRetrospective Studies030203 arthritis & rheumatologyBiological ProductsDrug Substitutionbusiness.industryModerate to severe psoriasisAdalimumabpsoriasisanti-TNFpersistenceMiddle Agedmedicine.diseaseUniversity hospitalSpainFemaleUstekinumabbusinessmedicine.drugJournal of Dermatological Treatment
researchProduct

A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudin…

2021

AbstractBackgroundPsoriasis is a chronic immune-mediated inflammatory skin disease which can also involve joints. It is often associated with burdensome comorbidities which negatively impact prognosis and quality of life (QoL). Biologic agents have been shown to be effective in controlling disease progression, but their use is associated with higher costs compared with traditional systemic treatments. The economic analysis of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: an obserVAtional longitudinal study of real-life clinical practice) study aims to assess the costs and cost-effectiveness of biologics in a real-world context in Italy.MethodsThe annualised…

Response ratemedicine.medical_specialtyCost per responderBiologicCostIxekizumabLongitudinal StudieContext (language use)Secukinumab.Severity of Illness IndexAntibodiesIndirect costsSettore MED/35Quality of lifeInternal medicinePsoriasisUstekinumabMonoclonalAdalimumab; Ixekizumab; Antibodies Monoclonal; Longitudinal Studies; Quality of Life; Psoriasis; Treatment Outcome; Severity of Illness Index; Italy; Humans; Biological Therapy; Ustekinumab; Secukinumab; Response rate; Real-world; Ixekizumab; Cost per responder; BiologicmedicineAdalimumabHumansPsoriasisLongitudinal Studieshealth care economics and organizationsSecukinumabPsoriasiAdalimumab; Biologic; Cost per responder; Costs; Ixekizumab; Real-world; Response rate; Secukinumab; Ustekinumab; Antibodies Monoclonal; Biological Therapy; Humans; Italy; Longitudinal Studies; Severity of Illness Index; Treatment Outcome; Psoriasis; Quality of Lifebusiness.industryHealth PolicyResearchAdalimumabAntibodies Monoclonalmedicine.diseaseCostsBiological TherapyIxekizumabTreatment OutcomeReal-worldItalyQuality of LifeSecukinumabUstekinumabPublic aspects of medicineRA1-1270Settore MED/35 - MALATTIE CUTANEE E VENEREEbusinessHumanmedicine.drugBMC Health Services Research
researchProduct

Update on the Management of Pediatric Psoriasis: An Italian Consensus

2022

Introduction Psoriasis affects children with a considerable burden in early life. Treating pediatric psoriasis is challenging also because of the lack of updated specific guidelines. With the recent approval of several biologics for pediatric psoriasis and the ongoing COVID-19 pandemic, the management of young psoriatic patients is facing major changes. A revision of treatment recommendations is therefore needed. Methods In September 2021, a board of six Italian dermatologists convened to update treatment recommendations. The board issued evidence- and consensus-based statements covering relevant areas of pediatric psoriasis, namely: assessment of psoriasis severity, management of children …

Topical corticosteroidsAdolescentBiologicSystemic therapyCorticosteroid-sparingHealth-related quality of lifePediatric psoriasisDermatologyBiologicsAdolescentsPlaque psoriasiAdolescents; Biologics; Children; Corticosteroid-sparing; Health-related quality of life; Pediatric psoriasis; Plaque psoriasis; Systemic therapy; Topical corticosteroidsSettore MED/35Pediatric psoriasiPlaque psoriasisSettore MED/35 - MALATTIE CUTANEE E VENEREEChildren
researchProduct

[Cardiovascular risk profile of patients with psoriasis].

2013

The aim of this study was to assess the cardiovascular risk profile of patients with psoriasis compared to patients without psoriasis. A case-control assay was performed using 143 cases (psoriasis patients) and 104 controls (patients without psoriasis). We assessed the presence of hypertension, lipid profile (HDL, triglycerides), diabetes, and body mass index in both cases and controls. Psoriasis patients showed an unfavorable cardiovascular risk profile and a higher risk of cardiovascular events and metabolic syndrome than patients without psoriasis.

Cardiovascular risk psoriasis
researchProduct

Simultaneous diagnosis of Kaposi’s sarcoma, psoriasis,vitiligo and monoclonal gammopathy of undetermined significance in an immunocompetent patient

2013

Kaposi’s sarcoma psoriasis vitiligo and monoclonal gammopathy of undetermined significanceSettore MED/35 - Malattie Cutanee E Veneree
researchProduct

Secukinumab efficacy in the treatment of nail psoriasis: a case series

2018

Nail involvement is frequent in patients with psoriasis, especially those with psoriatic arthritis (PsA), and can significantly impair quality of life (QoL). It is typically difficult to treat compared with skin lesions, although several conventional treatment options are available. The aim of this article is to describe our experience in the treatment of nail psoriasis with secukinumab in a case series. Fifteen patients (11 males and 4 females), with moderate-severe plaque psoriasis and nail psoriasis, eligible for systemic therapy, and received secukinumab. The Psoriasis Area and Severity Index (PASI) and body surface area (BSA) assessed cutaneous severity. Nail Psoriasis Severity Index (…

0301 basic medicineAdultMalemedicine.medical_specialtyDermatologyNail psoriasisAntibodies Monoclonal HumanizedSeverity of Illness Index030207 dermatology & venereal diseases03 medical and health sciencesPsoriatic arthritisNail Diseases0302 clinical medicineQuality of lifePsoriasisSeverity of illnessMedicineHumansPsoriasisIn patientPsoriasibusiness.industrysecukinumabfungifood and beveragesAntibodies MonoclonalMiddle Agedmedicine.diseaseNail DiseaseDermatologyhumanities030104 developmental biologyNAPSITreatment OutcomeNail diseasenail psoriasiQuality of LifeSecukinumabFemalebusinessHuman2708
researchProduct